The FDA has approved Auvelity as the first non-antipsychotic treatment for agitation in Alzheimer's disease, marking a major ...

Biogen stock heads for its worst single-day drop since July 2024 on the heels of new clinical data.

New research reveals a statistical technique used in Alzheimer's drug trials inflates clinical efficacy claims by 29x.

A statistical approach being used to support a new class of Alzheimer's drugs may lead to overstated claims about how the ...

One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the ...

Biogen Inc. said it will continue development of its experimental Alzheimer’s drug after getting promising though not ...

In the last few years, progress has been made in the fight against Alzheimer’s disease with a class of therapies called anti-amyloid antibodies (anti-Aβ). These anti-Aβ therapies, like lecanumab ...

Bob covers the money in health care, focusing on health insurance and hospitals. His stories delve into Medicare Advantage, opaque prescription drug benefits, and how much executives actually make. He ...

Drugs designed to clear amyloid beta from the brain—once seen as a promising path to slowing Alzheimer’s—may not actually ...

Dear Doctors: I understand that there is treatment for the beginning stages of Alzheimer’s disease that can stave off serious decline. There are also new tests to determine if a person is in the ...

Drugs designed to eliminate amyloid beta proteins from the brains of people diagnosed with Alzheimer’s disease do not provide a “clinically meaningful” benefit and raise the risk of brain swelling and ...